AnaptysBio’s (ANAB) “Outperform” Rating Reaffirmed at Wedbush
Wedbush restated their outperform rating on shares of AnaptysBio, Inc. (NASDAQ:ANAB) in a research note published on Friday. They currently have a $75.00 price target on the biotechnology company’s stock, up from their prior price target of $37.00. Wedbush also issued estimates for AnaptysBio’s Q1 2018 earnings at ($0.56) EPS, Q2 2018 earnings at ($0.61) EPS, Q3 2018 earnings at ($0.66) EPS, Q4 2018 earnings at ($0.72) EPS, FY2018 earnings at ($2.55) EPS, FY2019 earnings at ($2.95) EPS, FY2020 earnings at ($3.08) EPS and FY2021 earnings at ($1.81) EPS.
A number of other research analysts have also weighed in on the stock. Zacks Investment Research lowered shares of AnaptysBio from a buy rating to a hold rating in a research report on Wednesday, October 11th. Robert W. Baird set a $69.00 price objective on shares of AnaptysBio and gave the stock a buy rating in a report on Wednesday, October 11th. Royal Bank Of Canada raised their price objective on shares of AnaptysBio from $40.00 to $79.00 and gave the stock an outperform rating in a report on Tuesday, October 10th. Credit Suisse Group raised their price objective on shares of AnaptysBio from $38.00 to $85.00 and gave the stock an outperform rating in a report on Tuesday, October 10th. Finally, JMP Securities raised their price objective on shares of AnaptysBio from $45.00 to $82.00 and gave the stock an outperform rating in a report on Tuesday, October 10th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. AnaptysBio currently has an average rating of Buy and an average target price of $71.71.
AnaptysBio (NASDAQ ANAB) opened at 66.72 on Friday. The stock’s 50 day moving average is $36.95 and its 200 day moving average is $27.78. The firm’s market capitalization is $1.36 billion. AnaptysBio has a 1-year low of $15.17 and a 1-year high of $74.00.
AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.29. The firm had revenue of $7.00 million for the quarter, compared to the consensus estimate of $3.45 million. Analysts predict that AnaptysBio will post ($1.99) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “AnaptysBio’s (ANAB) “Outperform” Rating Reaffirmed at Wedbush” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2017/10/17/anaptysbios-anab-outperform-rating-reaffirmed-at-wedbush.html.
In other news, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of AnaptysBio stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total value of $901,924.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Holdings A/S Novo sold 70,706 shares of AnaptysBio stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $23.31, for a total transaction of $1,648,156.86. Following the completion of the transaction, the insider now owns 3,009,949 shares of the company’s stock, valued at approximately $70,161,911.19. The disclosure for this sale can be found here. Insiders sold 1,133,940 shares of company stock valued at $24,223,316 in the last quarter.
Several institutional investors and hedge funds have recently bought and sold shares of ANAB. Bank of America Corp DE purchased a new position in shares of AnaptysBio in the first quarter worth about $123,000. DAFNA Capital Management LLC increased its stake in shares of AnaptysBio by 22.2% in the second quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 1,000 shares in the last quarter. New York State Common Retirement Fund purchased a new position in shares of AnaptysBio in the second quarter worth about $168,000. TIAA CREF Investment Management LLC purchased a new position in shares of AnaptysBio in the first quarter worth about $227,000. Finally, Teachers Advisors LLC increased its stake in shares of AnaptysBio by 23.4% in the second quarter. Teachers Advisors LLC now owns 9,520 shares of the biotechnology company’s stock worth $228,000 after purchasing an additional 1,807 shares in the last quarter. Hedge funds and other institutional investors own 71.35% of the company’s stock.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Stock Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related stocks with our FREE daily email newsletter.